NEW YORK (GenomeWeb) – MDx Health has launched its planned bladder cancer test, a liquid biopsy assay that analyzes methylation in three genes — TWIST1, ONECUT2, and OTX1 — along with mutations in three others.
Like the firm's existing prostate cancer test, ConfirmMDx, the new AssureMDx bladder test is designed to help physicians pick out patients who have a low-risk of having cancer and thus can avoid more invasive tests.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
